Beyond ketosis: the search for the mechanism underlying SGLT2-inhibitor benefit continues

This is a commentary on a study in the same journal issue that compared sodium glucose cotransporter 2 inhibitors (SGLT2i) with exogenous ketones in metabolic flux studies. It notes that proposed mechanisms for SGLT2i benefit in heart failure include enhanced ketogenesis, and that the flux studies suggest differential effects of SGLT2i and exogenous ketones. The abstract reports no numerical data or sample sizes.